IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
iBio, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 28, 2026
$0.76−0.01 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $110.48M
- P/E (TTM)
- –
- Dividend yield
- –
iBio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | iBio | Industry median |
|---|---|---|
| Market Cap | $48.88M | $197.05M |
| Enterprise Value | -$39.16M | $106.56M |
| PS Ratio | 488.80 | 3.93 |
| PB Ratio | 0.57 | 2.14 |
| P/TBV Ratio | 0.58 | 2.46 |
Enterprise value
| Measure | iBio | Industry median |
|---|---|---|
| EV / Sales | -391.59 | 2.69 |
Income (trailing twelve months)
| Measure | iBio | Industry median |
|---|---|---|
| Revenue | $100.00K | $57.94M |
| Operating Income | -$35.14M | -$21.44M |
| Net Income | -$33.04M | -$22.46M |
| EBITDA | -$35.14M | -$16.91M |
| EPS (Diluted) | -$0.32 | -$0.83 |
Margins
| Measure | iBio | Industry median |
|---|---|---|
| Operating Margin | -35141.0% | -44.5% |
| Profit Margin | -33044.0% | -39.2% |
| EBITDA Margin | -35141.0% | -31.3% |
| FCF Margin | -23796.0% | -8.85% |
Returns
| Measure | iBio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -65.7% | -53.1% |
| Return on Assets (ROA) | -54.0% | -41.0% |
| Return on Invested Capital (ROIC) | -1397.9% | -32.0% |
| Return on Capital Employed (ROCE) | -40.2% | -37.8% |
Growth
| Measure | iBio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -75.0% | 6.01% |
| Revenue Growth (5Y CAGR) | -46.9% | 6.42% |
Balance sheet
| Measure | iBio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $88.04M | $62.42M |
| Net Cash (Debt) | $88.04M | $15.68M |
| Net Cash Per Share | $1.37 | $0.65 |
| Equity (Book Value) | $85.71M | $48.79M |
| Book Value Per Share | $1.33 | $1.36 |
| Tangible Book Value | $83.89M | $23.06M |
| Working Capital | $80.48M | $75.77M |
Financial position
| Measure | iBio | Industry median |
|---|---|---|
| Current Ratio | 7.85 | 3.30 |
| Quick Ratio | 7.50 | 2.39 |
| Interest Coverage | -663.04 | -7.12 |
Cash flow (trailing twelve months)
| Measure | iBio | Industry median |
|---|---|---|
| Operating Cash Flow | -$23.22M | -$12.35M |
| Capital Expenditures | -$578.00K | -$1.06M |
| Free Cash Flow | -$23.80M | -$20.28M |
| FCF Per Share | -$0.37 | -$0.41 |
Efficiency
| Measure | iBio | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $4.35K | $398.96K |
| Profits Per Employee | -$1.44M | -$732.08K |
| Employee Count | 23 | 73 |
Dividends and yields
| Measure | iBio | Industry median |
|---|---|---|
| Earnings Yield | -67.6% | -21.2% |
| FCF Yield | -48.7% | -7.64% |
| Buyback Yield | -7.22% | -0.58% |
| Shareholder Yield | -7.22% | 0.00% |
Shares
| Measure | iBio | Industry median |
|---|---|---|
| Shares Outstanding | 64,307,300 | 59,128,900 |
| Shares Change (YoY) | 891.1% | 11.1% |
| Shares Change (QoQ) | 61.2% | 0.54% |
| Float | 64,002,400 | 48,744,500 |
| Shares Held by Insiders | 0.47% | 11.8% |
| Shares Held by Institutions | 54.0% | 59.4% |
Taxes
| Measure | iBio | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | iBio | Industry median |
|---|---|---|
| Altman Z-Score | -3.17 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from iBio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.